The Lymphoma Channel is supported with funding from AstraZeneca (Diamond), BMS (Gold), Johnson & Johnson (Gold), Takeda (Silver) and Galapagos (Bronze).
VJHemOnc is an independent medical education platform. Supporters, including channel supporters, have no influence over the production of content. The levels of sponsorship listed are reflective of the amount of funding given to support the channel.
EHA 2026 | Insights into the KEYFORM-008 trial: favezelimab plus pembrolizumab versus chemotherapy for HL.
Guilherme Perini, MD, Hospital Israelita Albert Einstein, São Paulo, Brazil, presents findings from the Phase II KEYFORM-008 (NCT05508867) trial comparing the combination of favezelimab and pembrolizumab with standard chemotherapy in patients with relapsed/refractory classical Hodgkin lymphoma (HL). Dr Perini notes that, despite favorable efficacy outcomes observed in the favezelimab plus pembrolizumab group, which suggest that the dual blockade of anti-LAG-3 and PD-1 can improve responses, implementation in clinical practice remains challenging. This interview took place at the 31st Congress of the European Hematology Association (EHA) in Stockholm, Sweden.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
